<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00458744</url>
  </required_header>
  <id_info>
    <org_study_id>ADVL0613</org_study_id>
    <secondary_id>COG-ADVL0613</secondary_id>
    <secondary_id>CDR0000538359</secondary_id>
    <nct_id>NCT00458744</nct_id>
  </id_info>
  <brief_title>Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment</brief_title>
  <official_title>A Phase I Study Of Talotrexin (PT-523) In Children And Adolescents With Recurrent Solid Tumors Or Recurrent/Refractory Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the&#xD;
      growth of cancer cells, either by killing the cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of talotrexin in&#xD;
      treating young patients with recurrent solid tumors or leukemia that is recurrent or does not&#xD;
      respond to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Estimate the maximum tolerated dose (MTD) and recommended phase II dose of talotrexin in&#xD;
           younger patients with recurrent solid tumors or recurrent or refractory leukemia.&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the antitumor activity of this drug in these patients.&#xD;
&#xD;
        -  Assess the tolerability of the defined MTD of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to&#xD;
      diagnosis (solid tumor vs leukemia).&#xD;
&#xD;
        -  Stratum 1 (recurrent solid tumor): Patients receive talotrexin IV over 10 minutes on&#xD;
           days 1 and 8. Treatment repeats every 21 days for up to 17 courses in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of talotrexin until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity (DLT).&#xD;
&#xD;
        -  Stratum 2 (recurrent or refractory leukemia): A cohort of 3-6 patients with leukemia&#xD;
           receive treatment as in stratum 1 at the MTD determined in stratum 1. If 2 or 3 or 2 of&#xD;
           6 patients experience a DLT at the solid tumor MTD, accrual is stopped.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study withdrawn because of toxicity reported on the adult phase 1 trial.&#xD;
  </why_stopped>
  <start_date>February 2007</start_date>
  <primary_completion_date type="Anticipated">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of talotrexin</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>talotrexin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of either of the following:&#xD;
&#xD;
               -  Recurrent solid tumor&#xD;
&#xD;
                    -  Histologically confirmed* malignancy at original diagnosis or relapse&#xD;
&#xD;
                    -  Measurable or evaluable disease&#xD;
&#xD;
                    -  Lymphoma or primary CNS tumor allowed&#xD;
&#xD;
                         -  Patients with CNS tumors must be on a stable or decreasing dose of&#xD;
                            dexamethasone for the past 7 days&#xD;
&#xD;
               -  Recurrent or refractory leukemia&#xD;
&#xD;
                    -  Confirmed relapse, as defined by M3 marrow (25% blasts in bone marrow&#xD;
                       aspirate or biopsy)&#xD;
&#xD;
                    -  Active extramedullary disease allowed provided there is no leptomeningeal&#xD;
                       involvement NOTE: *Histological confirmation not required for intrinsic&#xD;
                       brain stem tumors&#xD;
&#xD;
          -  Bone marrow metastases allowed&#xD;
&#xD;
               -  Not refractory to red blood cell or platelet transfusion&#xD;
&#xD;
          -  No pleural effusion or significant ascites&#xD;
&#xD;
          -  No known curative therapy or therapy proven to prolong survival with an acceptable&#xD;
             quality of life exists&#xD;
&#xD;
          -  No Down syndrome&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status (PS) 50-100% (for patients &gt; 10 years of age) OR Lansky&#xD;
             PS 50-100% (for patients ≤ 10 years of age)&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm³ (for patients with solid tumors without bone&#xD;
             marrow involvement)&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³ (transfusion independent)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR&#xD;
             creatinine adjusted according to age as follows:&#xD;
&#xD;
               -  No greater than 0.6 mg/dL (1 year to 23 months)&#xD;
&#xD;
               -  No greater than 0.8 mg/dL (2 to 5 years)&#xD;
&#xD;
               -  No greater than 1.0 mg/dL (6 to 9 years)&#xD;
&#xD;
               -  No greater than 1.2 mg/dL (10 to 12 years)&#xD;
&#xD;
               -  No greater than 1.4 mg/dL (13 years and over [female])&#xD;
&#xD;
               -  No greater than 1.5 mg/dL (13 to 15 years [male])&#xD;
&#xD;
               -  No greater than 1.7 mg/dL (16 years and over [male])&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT ≤ 110 U/L (ULN is 45 U/L)&#xD;
&#xD;
          -  Albumin ≥ 2 g/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No known condition that, in the opinion of the investigator, would preclude study&#xD;
             compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from all prior treatment-related toxicity&#xD;
&#xD;
          -  At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea)&#xD;
             (for patients with solid tumors)&#xD;
&#xD;
          -  At least 24 hours since prior cytoreduction therapy initiated with hydroxyurea (for&#xD;
             patients with leukemia)&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy (small port)&#xD;
&#xD;
          -  At least 6 months since prior total-body irradiation (TBI), craniospinal radiotherapy,&#xD;
             or ≥ 50% radiotherapy to the pelvis&#xD;
&#xD;
          -  At least 6 weeks since prior substantial bone marrow radiotherapy&#xD;
&#xD;
          -  At least 3 months since prior stem cell transplant or rescue without TBI&#xD;
&#xD;
               -  No evidence of active graft-versus-host disease&#xD;
&#xD;
          -  At least 7 days since prior growth factor therapy&#xD;
&#xD;
          -  At least 7 days since prior biological therapy&#xD;
&#xD;
          -  No nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin or other salicylates,&#xD;
             penicillins, sulfa drugs (bactrim, septra), ciprofloxacin, tetracycline, thiazide&#xD;
             diuretics, or probenecid within 2 days prior to, during, or within 5 days after&#xD;
             treatment with talotrexin&#xD;
&#xD;
          -  No long-acting NSAIDs (e.g., nabumetone, naproxen, oxaprozin, piroxicam) within 5 days&#xD;
             prior to, during, or within 5 days after treatment with talotrexin&#xD;
&#xD;
          -  No concurrent investigational drugs&#xD;
&#xD;
          -  No concurrent anticancer agents or therapy (e.g., chemotherapy, radiotherapy,&#xD;
             immunotherapy, or biologic therapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Croop, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Riley's Children Cancer Center at Riley Hospital for Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sultan Ahmed Pradhan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tata Memorial Hospital</affiliation>
  </overall_official>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>April 9, 2007</study_first_submitted>
  <study_first_submitted_qc>April 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2007</study_first_posted>
  <last_update_submitted>August 7, 2014</last_update_submitted>
  <last_update_submitted_qc>August 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood grade I meningioma</keyword>
  <keyword>childhood grade II meningioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumors</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent childhood visual pathway glioma</keyword>
  <keyword>high-grade childhood cerebral astrocytoma</keyword>
  <keyword>low-grade childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood brain tumor</keyword>
  <keyword>childhood spinal cord tumor</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <keyword>childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent childhood pineoblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

